Cara Therapeutic Stock Filter Stocks by Fundamentals
CARA Stock | USD 0.67 0 0.30% |
Cara Therapeutic fundamentals help investors to digest information that contributes to Cara Therapeutic's financial success or failures. It also enables traders to predict the movement of Cara Stock. The fundamental analysis module provides a way to measure Cara Therapeutic's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cara Therapeutic stock.
Last Reported | Projected for Next Year | ||
Price To Sales Ratio | 1.92 | 1.82 |
Cara | Price to Sales |
Did you try this?
Run Portfolio Backtesting Now
Portfolio BacktestingAvoid under-diversification and over-optimization by backtesting your portfolios |
All Next | Launch Module |
Cara Fundamentals
Return On Equity | -1.1 | ||||
Return On Asset | -0.49 | ||||
Operating Margin | (10.85) % | ||||
Current Valuation | (18.94 M) | ||||
Shares Outstanding | 54.67 M | ||||
Shares Owned By Insiders | 14.58 % | ||||
Shares Owned By Institutions | 45.48 % | ||||
Number Of Shares Shorted | 2.58 M | ||||
Price To Earning | 62.54 X | ||||
Price To Book | 0.73 X | ||||
Price To Sales | 1.99 X | ||||
Revenue | 20.97 M | ||||
Gross Profit | (56.14 M) | ||||
EBITDA | (121.24 M) | ||||
Net Income | (118.51 M) | ||||
Cash And Equivalents | 157.51 M | ||||
Cash Per Share | 2.93 X | ||||
Total Debt | 43.17 M | ||||
Debt To Equity | 0.01 % | ||||
Current Ratio | 8.32 X | ||||
Book Value Per Share | 1.05 X | ||||
Cash Flow From Operations | (92.08 M) | ||||
Short Ratio | 3.51 X | ||||
Earnings Per Share | (2.19) X | ||||
Target Price | 5.23 | ||||
Number Of Employees | 55 | ||||
Beta | 0.7 | ||||
Market Capitalization | 38.66 M | ||||
Total Asset | 125.84 M | ||||
Retained Earnings | (684.75 M) | ||||
Working Capital | 90.57 M | ||||
Current Asset | 108.93 M | ||||
Current Liabilities | 5.27 M | ||||
Net Asset | 125.84 M |
About Cara Therapeutic Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cara Therapeutic's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cara Therapeutic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cara Therapeutic based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Cara Therapeutic in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Cara Therapeutic's short interest history, or implied volatility extrapolated from Cara Therapeutic options trading.
Pair Trading with Cara Therapeutic
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cara Therapeutic position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cara Therapeutic will appreciate offsetting losses from the drop in the long position's value.Moving together with Cara Stock
0.86 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
0.78 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
0.69 | ENVB | Enveric Biosciences Financial Report 20th of May 2024 | PairCorr |
Moving against Cara Stock
0.48 | ZURA | Zura Bio Limited Financial Report 10th of May 2024 | PairCorr |
The ability to find closely correlated positions to Cara Therapeutic could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cara Therapeutic when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cara Therapeutic - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cara Therapeutic to buy it.
The correlation of Cara Therapeutic is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cara Therapeutic moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cara Therapeutic moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cara Therapeutic can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Cara Therapeutic Piotroski F Score and Cara Therapeutic Altman Z Score analysis. For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Complementary Tools for Cara Stock analysis
When running Cara Therapeutic's price analysis, check to measure Cara Therapeutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cara Therapeutic is operating at the current time. Most of Cara Therapeutic's value examination focuses on studying past and present price action to predict the probability of Cara Therapeutic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cara Therapeutic's price. Additionally, you may evaluate how the addition of Cara Therapeutic to your portfolios can decrease your overall portfolio volatility.
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Transaction History View history of all your transactions and understand their impact on performance | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |
Is Cara Therapeutic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cara Therapeutic. If investors know Cara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cara Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.19) | Revenue Per Share 0.387 | Quarterly Revenue Growth (0.08) | Return On Assets (0.49) | Return On Equity (1.10) |
The market value of Cara Therapeutic is measured differently than its book value, which is the value of Cara that is recorded on the company's balance sheet. Investors also form their own opinion of Cara Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Cara Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cara Therapeutic's market value can be influenced by many factors that don't directly affect Cara Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cara Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cara Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cara Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.